Global S&T Development Trend Analysis Platform of Resources and Environment
CSIRO secures licence to develop medicinal cannabis | |
admin | |
2021-02-25 | |
发布年 | 2021 |
语种 | 英语 |
国家 | 澳大利亚 |
领域 | 地球科学 |
正文(英文) | Additional ResourcesAdditional Resources;Under a new licence, CSIRO will support the burgeoning local industry and partner with local manufacturers to drive the development of new cannabis therapeutics, in a move that will create new jobs in Australia. The global market for medicinal cannabis is projected to be worth USD $44 billion by 2024. CSIRO Scientist, Adjunct Professor Peter Duggan, said the licence placed CSIRO at the forefront of research into the development of new cannabis medicines. "Around the world, researchers are exploring the potential for medicinal cannabis to help with conditions such as epilepsy and the nausea and vomiting associated with chemotherapy treatment, multiple sclerosis and chronic pain," Professor Duggan said. "We had been able to do early-stage work with cannabis, but the new licence will enable us to develop cannabis-derived cannabinoid medicines using innovative extraction, refinement and formulation techniques." CSIRO is currently the only independent research institute in Australia able to develop drug manufacturing protocols in the medicinal cannabis space. This work will bridge the gap between the growing of plants and the manufacture of medicines, with the researchers developing the manufacturing protocols and preparing the first prototype products before transferring the technology to manufacturers for large scale production. The use of cannabis for medicinal purposes is highly regulated in Australia. However, in December the Therapeutic Goods Administration (TGA) approved over-the-counter pharmacy sales of a low dose form of cannabidiol (CBD), one of the key components of cannabis that can help with a range of medical conditions. Medicinal cannabis products, in the form of oils, capsules, oral sprays, lozenges or other drug formats, can also be prescribed through the TGA's Special Access Scheme. Peter Crock, CEO of industry leading medicinal cannabis company, Cann Group, and Chair of Medicinal Cannabis Industry Australia (MCIA), said there were over 20 medicinal cannabis companies currently listed on the ASX, and a growing number of licenced cultivators and manufacturers now in Australia. "Cann Group has worked closely with CSIRO over the past three years and has been pleased with the results," Mr Crock said. "With this independent license CSIRO will be able to play a key role in helping establish a vibrant industry in Australia. "Research that creates new and enhanced medical products and improves manufacturing processes is important if we want Australia's medicinal cannabis industry to be competitive in a global market." |
URL | 查看原文 |
来源平台 | Commonwealth Scientific and Industrial Research Organisation |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/316792 |
专题 | 地球科学 |
推荐引用方式 GB/T 7714 | admin. CSIRO secures licence to develop medicinal cannabis. 2021. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论